Between a rock and a hard place?
Developing small-molecule inhibitors against protein-protein interaction targets is among the most difficult challenges in contemporary drug discovery. Recent developments in our understanding of this problem, and in the knowledge and tools available to address it, give cause for renewed hope, but substantial challenges remain.
Whitty
Adrian
A
Drug Discovery Department, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA. adrian.whitty@biogenidec.com
Kumaravel
Gnanasambandam
G
D001665:Binding Sites / Q000187:drug effects; D018360:Crystallography, X-Ray; D015195:Drug Design; D006801:Humans; D008958:Models, Molecular; D008968:Molecular Conformation; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation; D011506:Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
D011506:Proteins